文献速递临床试验与 GCP基础与转化研究

生物阻抗体成分监测指导CRRT危重患者容量管理:VENUS随机对照试验方案

VolumE maNagement Under body composition monitoring in critically ill patientS on CRRT: study protocol for a randomized controlled trial (VENUS trial).
PubMed 文献 · Trials · 2018-12-12

本研究为多中心前瞻性随机对照试验,计划纳入244例接受CRRT的AKI患者,随机分为InBody S10生物阻抗指导容量管理组与仅依据临床信息管理组,干预7天。主要结局为CRRT启动后7天达到等容量状态的比例,次要结局为28天、60天和90天死亡率。

要点

  • 首次前瞻性评估生物阻抗指导CRRT患者容量管理能否提高等容量达标率。
  • 主要结局为CRRT启动后7天等容量状态比例,次要结局为28/60/90天死亡率。
  • 计划纳入244例CRRT治疗的AKI患者,随机分组干预7天。

核心结论

  • 这是首个探究生物阻抗指导容量管理能否使CRRT治疗的AKI患者达到等容量状态的临床试验。

研究设计与样本

  • 多中心、前瞻性、随机对照试验,计划纳入244例接受CRRT治疗的AKI患者。
  • 患者随机分为InBody S10生物阻抗指导管理组或仅依据临床信息容量管理组,干预7天。

关键数值与推荐

  • 主要结局为比较CRRT启动后7天等容量状态的比例。
  • 次要结局为比较两组28天、60天和90天死亡率。

临床怎么用

  • 若试验证实有效,生物阻抗可成为CRRT患者容量评估的辅助工具,弥补传统算术计算和医师主观判断的不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite recent technical advances in the management of acute kidney injury (AKI), such as continuous renal replacement therapy (CRRT), intensive care unit mortality is still high, at approximately 40 to 50%. Although several factors have been reported to predict mortality in AKI patients, fluid overload (FO) during CRRT is a well-known predictor of patient survival. However, FO has been mostly quantified as an arithmetical calculation and determined on the basis of the physicians' perception. Even though such quantification and assessment provides an easy evaluation of a patient's fluid status and is a simple method, it is not applicable unless a detailed record of fluid monitoring is available. Furthermore, the method cannot differentiate excess water in individual water compartments but can only reflect excess total body water. Bioimpedance analysis (BIA) has been used to measure the nutritional component of body composition and is a promising tool for the measurement of volume status. However, there has been no prospective interventional study for fluid balance among CRRT-treated AKI patients using BIA. Therefore, we will investigate the usefulness of fluid management using the InBody S10 (InBody®, Seoul, Korea), a BIA tool, compared with that of generally used quantification methods. METHODS/DESIGN: This will be a multicenter, prospective, randomized controlled trial. A total of 244 patients undergoing CRRT treatment will be enrolled and randomly assigned to receive either to InBody S10-guided management or to fluid management based only on clinical information for 7 days. The primary outcome is to compare the rate of euvolemic status 7 days after the initiation of CRRT, with a secondary outcome being to compare the 28-, 60-, and 90-day mortality rates between the two groups. DISCUSSION: This will be the first clinical trial to investigate the effect of using BIA-guided fluid management to achieve euvolemia in CRRT-treated AKI patients. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03330626 . Registered on 6 November 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Oh HJ, An JN, Oh S, et al. VolumE maNagement Under body composition monitoring in critically ill patientS on CRRT: study protocol for a randomized controlled trial (VENUS trial). Trials. 2018. PMID: 30541593. doi:10.1186/s13063-018-3056-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。